RBC
SRPT icon

Roble Belko & Company’s Sarepta Therapeutics SRPT Stock Holding History

Roble Belko & Company’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-8
Closed – – 486
2025
Q2 		$0 Hold
8
– – ﹤0.01% 476
2025
Q1 		$1K Hold
8
– – ﹤0.01% 382
2024
Q4 		$1K Buy
+8
New +$980 ﹤0.01% 357
2022
Q1 		– Sell
-8
Closed -$1K – 394
2021
Q4 		$1K Hold
8
– – ﹤0.01% 335
2021
Q3 		$1K Hold
8
– – ﹤0.01% 310
2021
Q2 		$1K Hold
8
– – ﹤0.01% 321
2021
Q1 		$1K Hold
8
– – ﹤0.01% 314
2020
Q4 		$1K Hold
8
– – ﹤0.01% 303
2020
Q3 		$1K Buy
+8
New +$1.22K ﹤0.01% 311

Other funds holding SRPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Roble Belko & Company's SRPT Position: Q3 2025 in Review

Roble Belko & Company sold out of Sarepta Therapeutics (SRPT) in Q3 2025, closing a stake of 8 shares.

Roble Belko & Company first reported a position in SRPT in Q3 2020 and held it in 9 quarters. The position peaked at $1K in Q1 2025. 319 funds tracked by Wall St. Rank hold SRPT as of Q3 2025.

  • Roble Belko & Company reported no remaining Sarepta Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Roble Belko & Company sold 8 Sarepta Therapeutics shares in Q3 2025.
  • Roble Belko & Company first reported a position in Sarepta Therapeutics in Q3 2020 and held it in 9 quarters.
  • Roble Belko & Company's Sarepta Therapeutics position peaked at $1K in Q1 2025.
  • 319 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2025.

Based on Roble Belko & Company's 13F filing for Q3 2025, filed 24 Oct 2025.